Bill Haney, Dragonfly CEO (Getty Images)
August 17, 2020 07:00 AM EDTUpdated 11:05 AM
Deals

Bris­tol My­ers bets $475M cash on a block­buster shot at break­ing the mold in im­muno-on­col­o­gy — with a po­ten­tial IL-12 game-chang­er

John Carroll

Editor & Founder

In the on­col­o­gy R&D world, IL-12 has a rep some­thing akin to ni­tro­glyc­er­ine in old Hol­ly­wood movies. It’s in­cred­i­bly pow­er­ful, but any false move and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Rev­o­lu­tion Med­i­cines breaks ground in chal­leng­ing pan­cre­at­ic can­cer with two RAS drugs

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Up­dat­ed: Pfiz­er's ac­tivist says board must 'hold man­age­ment ac­count­able' for R&D short­com­ings

Q3 biotech roundup: The 2024 turn­around sput­ters in­to a crit­i­cal Q4 fi­nale

Iterum wins ap­proval for new oral an­tibi­ot­ic for UTIs. Now it wants a part­ner

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times